Literature DB >> 1510944

Heparin binding to the urokinase kringle domain.

R W Stephens1, A M Bokman, H T Myöhänen, T Reisberg, H Tapiovaara, N Pedersen, J Grøndahl-Hansen, M Llinás, A Vaheri.   

Abstract

The binding of urokinase to immobilized heparin and dextran sulfate was studied using activity assays of the bound urokinase. The markedly higher binding observed with high M(r) urokinase compared to low M(r) urokinase indicated a role for the amino-terminal fragment (ATF). This was confirmed by the use of inactive truncated urokinase and monoclonal antibodies specific for the ATF in competition assays of urokinase binding. Antibody competition assays suggested a site in the kringle domain, and a synthetic decapeptide Arg-52-Trp-62 from the kringle sequence (kringle numbering convention) was competitive in assays of urokinase binding to dextran sulfate and heparin. Heparin binding to the urokinase kringle was unambiguously demonstrated via 1H NMR spectroscopy at 500 MHz. Effective equilibrium association constants (K(a)*) were determined for the interaction of isolated kringle fragment and low M(r) heparin at pH 7.2. The binding was strong in salt-free 2H2O (K(a)* approximately 57 mM-1) and remained significant in 0.15 M NaCl (K(a)* approximately 12 mM-1), supporting a potential physiological role for the interaction. This is the first demonstration of a function for the kringle domain of urokinase, and it suggests that while the classical kringle structure has specificity for lysine binding, there may also exist a class of kringles with affinity for polyanion binding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510944     DOI: 10.1021/bi00148a019

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Proteolytic disruption of laminin-integrin complexes on muscle cells during synapse formation.

Authors:  M J Anderson; Z Q Shi; S L Zackson
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

2.  Kringle-kringle interactions in multimer kringle structures.

Authors:  K Padmanabhan; T P Wu; K G Ravichandran; A Tulinsky
Journal:  Protein Sci       Date:  1994-06       Impact factor: 6.725

Review 3.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

4.  A systems biology approach for the investigation of the heparin/heparan sulfate interactome.

Authors:  Alessandro Ori; Mark C Wilkinson; David G Fernig
Journal:  J Biol Chem       Date:  2011-03-30       Impact factor: 5.157

5.  Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.

Authors:  Elisa Roztocil; Suzanne M Nicholl; Mark G Davies
Journal:  J Surg Res       Date:  2007-07       Impact factor: 2.192

6.  NMR solution structure of the neurotrypsin Kringle domain.

Authors:  Olga A Ozhogina; Alexander Grishaev; Emile L Bominaar; László Patthy; Maria Trexler; Miguel Llinás
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

7.  Structural/functional properties of the Glu1-HSer57 N-terminal fragment of human plasminogen: conformational characterization and interaction with kringle domains.

Authors:  S S An; D N Marti; C Carreño; F Albericio; J Schaller; M Llinas
Journal:  Protein Sci       Date:  1998-09       Impact factor: 6.725

8.  Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.

Authors:  T L Moser; J J Enghild; S V Pizzo; M S Stack
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

9.  Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.

Authors:  P Carmeliet; L Moons; M Dewerchin; S Rosenberg; J M Herbert; F Lupu; D Collen
Journal:  J Cell Biol       Date:  1998-01-12       Impact factor: 10.539

10.  Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

Authors:  A Knoop; P A Andreasen; J A Andersen; S Hansen; A V Laenkholm; A C Simonsen; J Andersen; J Overgaard; C Rose
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.